Despite the excitement surrounding the upcoming Anthropic IPO, many companies, including OpenAI and several data center firms, have delayed or canceled their IPO plans due to rising interest rates and market volatility. In contrast, the biotech sector has seen a significant uptick, with 26 biotech companies going public this year in the U.S., the highest number since 2021.
This surge is attributed to increased mergers and acquisitions by large pharmaceutical companies and advancements in medical science. However, historical data shows that biotech IPOs can be risky; only 16% of companies from the 2020 biotech IPO class have delivered positive returns, with many suffering substantial losses.
Investors are advised to consider companies that support the biotech industry rather than individual drug developers, as these 'picks and shovels' firms may offer more stable investment opportunities.
Additionally, potential investors should evaluate the development phase of a company's lead product, the total addressable market for its treatments, and the experience of its management team before investing in biotech IPOs